Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Ganfeborole and Microgynon in Healthy Females
NCT07784894Phase 1Recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganfeborole in Tuberculosis (TB), sponsored by GSK. Primary endpoints: Area under the plasma concentration-time curve over 24 hours of ethinylestradiol and levonorgestrel at Day 24 and Maximum observed concentration of ethinylestradiol and levonorgestrel at Day 24. Started Aug 2026; status: recruiting.
02
Drugs
ganfeborole
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07784894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784894.